BIBF1120(Vargatef)

• Catalog No.: S1010
• CAS Number: 928326-83-4
• M. F.: C31H33N5O4
• M. W.: 539.62482
• Storage: -20°C

SYNONYMS

• IUPAC name: methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate
• IUPAC Traditional name: methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-1H-indole-6-carboxylate
• Synonyms: Vargatef

DATABASE IDS

• CAS Number: 928326-83-4

PROPERTIES

• Target: VEGFR
• Target: PDGFR
• Target: FGFR
• Salt Data: Free Base
• Solubility: DMSO
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area

• Description: Non-small cell lung cancer

Biological Activity

• Description: BIBF1120 (Vargatef) is a potent inhibitor of VEGFR1, VEGFR2, VEGFR3 with IC50 of 34 nM, 5 nM and 5 nM, respectively.
• Targets: VEGFR1; VEGFR2; VEGFR3
• IC50: 34 nM ^[1]; 5 nM; 5 nM ^[2]
• In Vitro: BIBF1120 inhibits PDGFR kinase activity of PDGFR alpha and PDGFR beta types with IC50 values of 59 and 65 nM, respectively. In addition, BIBF1120 suppresses the FGFR subtypes with IC50 of 60 nM, 37 nM and 108 nM for FGFR1, FGFR2, and FGFR3, respectively. BIBF1120 binds to the ATP-binding site in the cleft between the amino and carboxy terminal lobes of the kinase domain. The indolinone scaffold forms two hydrogen bonds with the backbone nitrogen of Cys^919 and the backbone carbonyl oxygen of Glu^917 in the hinge region. BIBF 1120 inhibits proliferation of PDGF-BB stimulated BRPs with an EC50 of 79 nM in cell assays. BIBF1120 at concentrations as low as 100 nM blocks activation of MAPK after stimulation with 5% serum plus PDGF-BB. In cultures of human vascular smooth muscle cells (HUASMC), BIBF1120 prevents PDGF-BB stimulated proliferation with an EC50 of 69 nM. ^[1]
• In Vivo: In all tumor models tested thus far, including human tumor xenografts growing in nude mice and a syngeneic rat tumor model, BIBF1120 is highly active at well-tolerated doses (25-100 mg/kg daily p.o.). This is evident in the magnetic resonance imaging of tumor perfusion after 3 days, reducing vessel density and vessel integrity after 5 days, and profound growth inhibition. ^[1]
• Clinical Trials: BIBF1120 is currently in a Phase III clinical trial in treatment of ovarian neoplasms.

Combination Therapy

• Description: BIBF 1120 in combination with Pemetrexed in Calu-6 xenografts results in additive antitumor activity (T/C 23%) compared with single-agent treatment (T/C 37% and 42%, respectively). ^[2]

Protocol

• Protocol: Kinase Assay ^[3]
• VEGFR2 Kinase Assay: The cytoplasmic tyrosine kinase domain of VEGFR2 (residues 797-1355 according to sequence deposited in databank SWISS-PROT P35968) is cloned into pFastBac fused to GST and extracted. Enzyme activity is assayed in the presence or absence of serial dilutions of BIBF1120 performed in 25% DMSO. Each microtiter plate contains internal controls such as blank, maximum reaction, and historical reference compound. All incubations are conducted at room temperature on a rotation shaker. 10 μL of each BIBF1120 dilution is added to 10 μL of diluted kinase (0.8 μg/mL VEGFR2, 10 mM Tris pH 7.5, 2 mM EDTA, and 2 mg/mL BSA) and preincubated for 1 hour. The reaction is started by addition of 30 μL of substrate mix containing 62.4 mM Tris pH 7.5, 2.7 mM DTT, 5.3 mM MnCl₂, 13.3 mM Mg-acetate, 0.42 mM ATP, 0.83 mg/mL Poly-Glu-Tyr(4:1), and 1.7 μg/mL Poly-Glu-Tyr(4:1)-biotin and incubated for 1 hour. The reaction is stopped by addition of 50 μL of 250 mM EDTA, 20 mM HEPES, pH 7.4. 90 μL of the reaction mix is transferred to a streptavidin plate and incubated for 1-2 hours. After three washes with PBS the EU-labeled antibody, PY20 is added (recommended dilution 1:2000 of 0.5 mg/mL labeled antibody in DELFIA assay buffer). Excessive detection antibody is removed by three washes of DELFIA washing buffer. Then 10 minutes before measurement on the multilabel reader, each well is incubated with 100 μL of DELFIA enhancement solution.
• Protocol: Cell Assay ^[1]
• Cell Lines: HUVEC, HUASMC, and BRP cell lines
• Concentrations: 50 nM
• Incubation Time: 2 hours
• Methods: The cell lines HUVEC, HUASMC, and BRP are used for the assay. BIBF1120 is added to the cultures two hours before the addition of ligands. Cell lysates are generated. Western blotting is done using standard SDS-PAGE methods, loading 50 to 75 μg of protein per lane. Detection was facilitated by enhanced chemiluminescence. Total and phosphorylated mitogen-activated protein kinase (MAPK) is analyzed using monoclonal antibodies M3807 and M8159. Total Akt is detected using the corresponding polyclonal antibody and phosphorylated Akt (Ser473) is analyzed by using its monoclonal antibody. Monoclonal antibody is also used to detect cleaved caspase-3 while KDR (VEGFR2) protein is detected using a corresponding antibody.
• Protocol: Animal Study ^[1]
• Animal Models: FaDu, Caki-1, SKOV-3, H460, HT-29, or PAC-120 xenografts in Athymic NMRI-nu/nu female mice
• Formulation: In a 0.5 % Natrosol solution
• Doses: 100 mg/kg
• Administration: p.o.

References

• References: [1] Hilberg F, et al. Cancer Res, 2008, 68(12), 4774-4782.
• References: [2] Frank H, et al. J Thorac Oncol, 2007, 2(8), S380.
• References: [3] Roth GJ, et al. J Med Chem, 2009, 52(14), 4466-4480.

REFERENCES

• Hilberg F, et al. Cancer Res, 2008, 68(12), 4774-4782.
• Frank H, et al. J Thorac Oncol, 2007, 2(8), S380.
• Roth GJ, et al. J Med Chem, 2009, 52(14), 4466-4480.